BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37531290)

  • 1. Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Paraqindes H; Mourksi NE; Ballesta S; Hedjam J; Bourdelais F; Fenouil T; Picart T; Catez F; Combe T; Ferrari A; Kielbassa J; Thomas E; Tonon L; Viari A; Attignon V; Carrere M; Perrossier J; Giraud S; Vanbelle C; Gabut M; Bergeron D; Scott MS; Castro Vega L; Magne N; Huillard E; Sanson M; Meyronet D; Diaz JJ; Ducray F; Marcel V; Durand S
    Neuro Oncol; 2023 Dec; 25(12):2191-2206. PubMed ID: 37531290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2'O-Ribose Methylation of Ribosomal RNAs: Natural Diversity in Living Organisms, Biological Processes, and Diseases.
    Jaafar M; Paraqindes H; Gabut M; Diaz JJ; Marcel V; Durand S
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corrigendum to: Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Neuro Oncol; 2023 Dec; 25(12):2305. PubMed ID: 37815168
    [No Abstract]   [Full Text] [Related]  

  • 4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
    Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
    Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
    Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
    J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
    Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
    Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
    PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
    Leu S; von Felten S; Frank S; Boulay JL; Mariani L
    J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
    Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
    Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
    Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasively evaluating the grade and IDH mutation status of gliomas by using mono-exponential, bi-exponential diffusion-weighted imaging and three-dimensional pseudo-continuous arterial spin labeling.
    Guo D; Jiang B
    Eur J Radiol; 2023 Mar; 160():110721. PubMed ID: 36738600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.
    Bader JM; Deigendesch N; Misch M; Mann M; Koch A; Meissner F
    Cell Rep Med; 2023 Jan; 4(1):100877. PubMed ID: 36584682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of immune phenotype with IDH mutation in diffuse glioma.
    Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
    Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.
    Mamatjan Y; Voisin MR; Nassiri F; Moraes FY; Bunda S; So J; Salih M; Shirahata M; Ono T; Shimizu H; Schrimpf D; von Deimling A; Aldape KD; Zadeh G
    Neuro Oncol; 2023 Nov; 25(11):2028-2041. PubMed ID: 37474126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.